Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...

Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead ...

Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based ...

Shares of Sarepta Therapeutics SRPT have soared 43% year to date, significantly outperforming the industry’s 6.9% decline.

Sarepta Therapeutics has turned to dealmaking to restock a drug pipeline analysts worried was growing thin, announcing ...

Sarepta Therapeutics Inc. has a plan in place to significantly expand the diseases it treats beyond Duchenne muscular ...

Commerce Bank boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 15.7% in the 3rd quarter, ...

Analysts at HC Wainwright issued their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors ...

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...

TD Cowen analyst Ritu Baral maintained a Buy rating on Vera Therapeutics (VERA – Research Report) today. The company’s shares closed yesterday ...